HLA-C and neoplasm: Our recent unpublished preclinical work with collaborators at the Georgia Institute of Technology suggests that the affinity of the TCR for its cognate peptide–MHC, and the force of the resulting bonds between them, are impaired in the tumor microenvironment but can be restored with statin therapy [34].